RT Journal Article
T1 Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
A1 Marcé, Sílvia
A1 Xicoy, Blanca
A1 García, Olga
A1 Cabezón, Marta
A1 Estrada, Natalia
A1 Vélez, Patricia
A1 Boqué, Concepción
A1 Sagüés, Miguel
A1 Angona, Anna
A1 Teruel Montoya, Raúl
A1 Ferrer Marín, Francisca
A1 Amat, Paula
A1 Hernández Boluda, Juan
A1 Ibarra, Mariana
A1 Anguita Mandly, Eduardo Luis
A1 Cortés, Montserrat
A1 Fernández Ruiz, Andrés
A1 Fontanals, Sandra
A1 Zamora, Lurdes
AB The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response (DMR) and its duration (sDMR), progression rate (CIP), overall survival (OS), and treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing the e13a2 and 126 the e14a2, and correlated the differential transcript expression with the above-mentioned parameters. There were no differences in the cumulative incidence of cytogenetic responses nor in the acquisition of DMR and sDMR between the two groups, but the e14a2 transcript had a positive impact on molecular response during the first 6 months, whereas the e13a2 was associated with improved long-term OS. No correlation was observed between the transcript type and TFR rate.
PB MPDI
SN 2077-0383
YR 2021
FD 2021-07-16
LK https://hdl.handle.net/20.500.14352/4786
UL https://hdl.handle.net/20.500.14352/4786
LA eng
NO Marcé, S., Xicoy, B., García, O. et al. «Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib». Journal of Clinical Medicine, vol. 10, n.o 14, julio de 2021, p. 3146. DOI.org (Crossref), https://doi.org/10.3390/jcm10143146.
NO Instituto de Salud Carlos III (ISCIII)
NO Generalitat de Catalunya
DS Docta Complutense
RD 18 abr 2025